Global Follicle Stimulating Hormone (FSH) Market Trends, Business Overview, Industry Growth and Forecast to 2028

The global follicle stimulating hormone (FSH) market is anticipated to grow at a significant CAGR 5% during the forecast period (2022-2028). The gonadotropic hormone is secreted by the anterior pituitary gland. It supports in the development of pubertal maturation and the reproductive process. The major factor expected to drive the market is increasing adoption of assisted reproductive technology (ART) and the rising number of infertility patients seeking treatment. Moreover, hypothalamic disorders propel or increase in cases of pituitary gland tumor also boost the FSH market growth during the forecast period.

Follicle Stimulating Hormone (FSH) is a glycoprotein. FSH stimulates the development of follicles in the ovaries and spermatogenesis. Further, it is used for ovarian stimulation, induction of puberty, regulation of menstrual cycles during polycystic ovary syndrome (PCOS), spermiogenesis, and luteinization among infertile women. However, urinary follicle tests are gaining huge traction in young females attributing to high significance in determining menstrual irregularities for different age groups. Whereas, infertility treatment is gaining huge traction attributed to wide exposure to FSH tests and consulting followed by a significant rise in the adoption of FSH products by physicians.

Some major players in the market include Merck KGaA, Ferring Pharmaceuticals BV, and Teva Pharmaceuticals Industries Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2021, Institut Biochimique SA acquired 100% of the share capital of its French distributor Laboratoires Genevrier SAS. Institut Biochimique SA and Laboratoires Genevrier SAS have been collaborating successfully for more than 30 years. The acquisition is part of the group’s strategy aimed at strengthening its commercial opportunity for Institut Biochimique SA continuous growth in the French market a crucial area for the company.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

• Competitive Landscape- Merck KGaA, Ferring Pharmaceuticals BV, and Teva Pharmaceuticals Industries Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Follicle Stimulating Hormone (FSH) Market Report by Segment

By Type

• Recombinant FSH
• Urinary FSH

By Application

• Infertility Treatment
• Assisted Reproductive Technology

Global Follicle Stimulating Hormone (FSH) Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa